Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health‐related quality of life in patients with overactive bladder treated with tolterodine

Aims:  Relationships were evaluated between treatment‐related improvements in overactive bladder (OAB) symptoms as recorded in bladder diaries and patient‐reported symptom bother, bladder‐related problems and health‐related quality of life (HRQL).

[1]  K. Coyne,et al.  Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. , 2006, Urology.

[2]  K. Coyne,et al.  Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. , 2006, Urology.

[3]  I. Hussain,et al.  Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. , 2006, Urology.

[4]  V. Elinoff,et al.  Symptom‐specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial , 2006, International journal of clinical practice.

[5]  M. Rosenberg.  Overactive bladder made ridiculously simple? , 2006, International journal of clinical practice.

[6]  R. Roberts,et al.  Tolterodine extended release improves patient‐reported outcomes in overactive bladder: results from the IMPACT trial , 2006, International journal of clinical practice.

[7]  L. Matza,et al.  The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. , 2006, European urology.

[8]  K. Coyne,et al.  TOLTERODINE EXTENDED RELEASE (ER) FOR OVERACTIVE BLADDER (OAB): CORRELATIONS AMONG IMPROVEMENTS IN OBJECTIVE SYMPTOMS, PATIENT PERCEPTION OF BLADDER CONDITION (PPBC), AND HEALTH-RELATED QUALITY OF LIFE (HRQL) , 2006 .

[9]  P. Abrams,et al.  Impact of overactive bladder symptoms on employment, social interactions and emotional well‐being in six European countries , 2006, BJU international.

[10]  M. Rosenberg,et al.  Overactive bladder in women: symptom impact and treatment expectations , 2005, Current medical research and opinion.

[11]  L. Matza,et al.  Test‐retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB‐q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) , 2005, Neurourology and urodynamics.

[12]  L. Matza,et al.  The responsiveness of the Overactive Bladder Questionnaire (OAB-q) , 2005, Quality of Life Research.

[13]  R. Willke,et al.  Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. , 2004, Controlled clinical trials.

[14]  Y. Homma,et al.  Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial , 2004, World Journal of Urology.

[15]  D. Revicki,et al.  The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Ingela Wiklund,et al.  Assessment of patient‐reported outcomes in clinical trials: the example of health‐related quality of life , 2004, Fundamental & clinical pharmacology.

[17]  D. Fairclough,et al.  Patient reported outcomes as endpoints in medical research , 2004, Statistical methods in medical research.

[18]  Teh-Wei Hu,et al.  Costs of urinary incontinence and overactive bladder in the United States: a comparative study. , 2004, Urology.

[19]  C. Thompson,et al.  The prevalence of nocturia and its effect on health‐related quality of life and sleep in a community sample in the USA , 2003, BJU international.

[20]  C. Thompson,et al.  The impact on health‐related quality of life of stress, urge and mixed urinary incontinence , 2003, BJU international.

[21]  T. Wagner,et al.  Estimated economic costs of overactive bladder in the United States. , 2003, Urology.

[22]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[23]  C. Kelleher,et al.  Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. , 2002, The American journal of managed care.

[24]  D. Revicki,et al.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q , 2002, Quality of Life Research.

[25]  D. Lama,et al.  A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). , 2002, Clinical therapeutics.

[26]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[27]  R. Lipton,et al.  Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. , 2001, Urology.

[28]  C. Kelleher,et al.  Overactive bladder significantly affects quality of life. , 2000, The American journal of managed care.

[29]  D A Revicki,et al.  Recommendations for evaluating the validity of quality of life claims for labeling and promotion. , 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  A. Wein,et al.  The overactive bladder: an overview for primary care health providers. , 1999, International journal of fertility and women's medicine.

[31]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[32]  C. Kelleher,et al.  Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. , 2002, The American journal of managed care.